本文選題：非增殖期糖尿病視網膜病變 + 達明飲　； 參考：《黑龍江中醫(yī)藥大學》2017年碩士論文

【摘要】：目的:觀察中藥達明飲對非增殖期糖尿病視網膜病變(NPDR)氣陰兩虛、瘀血阻絡證血小板平均體積(MPV)、血小板分布寬度(PDW)、及大型血小板比率(P-LCR)的影響,探討該藥可能的作用機理。方法:將符合入選標準的非增殖期糖尿病視網膜病變氣陰兩虛、瘀血阻絡證患者共31例(62只眼),隨機分為治療組16例(32只眼)和對照組1 5例(30只眼)。治療組予達明飲口服,對照組予羥苯磺酸鈣口服,此兩組療程均為30天。觀察治療前后兩組MPV、PDW、P-LCR、視力、眼底、FFA、中醫(yī)證候等臨床癥狀的改善情況,并將兩組結果進行統(tǒng)計學分析。結果:(1)經30日治療后,治療組的總有效率為87.5%,對照組總有效率為76.7%,且治療組療效明顯優(yōu)于對照組,說明兩組之間差異有統(tǒng)計學意義(P0.05)。(2)治療后,兩組的MPV、PDW均有改善,治療組的改善情況優(yōu)于對照組,兩組的療效差異具有統(tǒng)計學意義(P0.05)。(3)治療前后對比,兩組的P-LCR均有改善,治療組的改善情況優(yōu)于對照組,但治療后兩組的療效差異不具有統(tǒng)計學意義(P0.05)。(4)用藥30天后,兩組視力均有提高,且二者差異有統(tǒng)計學意義(P0.05);治療組視力的提高優(yōu)于對照組。(5)治療后,治療組與對照組眼底均有改善,治療組對眼底改善優(yōu)于對照組,有統(tǒng)計學意義(P0.05)。(6)治療后,治療組中醫(yī)證候積分有改善,對照組中醫(yī)證候積分無明顯改善,治療組治療前后差異有統(tǒng)計學意義(P0.01),治療組明顯優(yōu)于對照組。(7)治療后,治療組的中醫(yī)證候療效總有效率為81.3%,對照組總有效率為13.3%,且治療組中醫(yī)證候療效明顯優(yōu)于對照組,兩組之間差異有統(tǒng)計學意義(P0.01)。結論:中藥達明飲對氣陰兩虛、瘀血阻絡證NPDR的患者的MPV PDW、P-LCR有明顯的干預作用,同時改善NPDR的證候及視功能。其作用機制可能是從整體上調節(jié)機體內環(huán)境,減輕毛細血管壁的阻塞及損傷,降低毛細血管通透性,保護血管內屏障,改善視網膜的微循環(huán)從而治療并控制NPDR的發(fā)生和發(fā)展。
[Abstract]:Objective: to observe the effects of Daming decoction on the average volume of platelet MPV, platelet distribution width and large platelet ratio P-LCRs in patients with non-proliferative diabetic retinopathy with deficiency of qi and yin, blood stasis and obstruction of collaterals, and to explore the possible mechanism of the drug.Methods: a total of 31 cases (62 eyes) of diabetic retinopathy with deficiency of qi and yin and stagnation of blood and collaterals were randomly divided into treatment group (n = 16, n = 32) and control group (n = 15, n = 30).The treatment group was treated with Daming Yin and the control group with calcium dobesilate for 30 days.The improvement of clinical symptoms such as MPV PDWN P-LCR, visual acuity, fundus FFAand TCM syndromes were observed before and after treatment, and the results of the two groups were analyzed statistically.Results after 30 days of treatment, the total effective rate of the treatment group was 87.5, and the total effective rate of the control group was 76.70.The curative effect of the treatment group was obviously better than that of the control group, which indicated that the difference between the two groups was statistically significant (P 0.05).The improvement of the treatment group was better than that of the control group, and the difference between the two groups was statistically significant. The P-LCR of the two groups was improved, and the improvement of the treatment group was better than that of the control group.However, the difference of curative effect between the two groups was not statistically significant 30 days after treatment, the visual acuity of the two groups was improved, and the difference was statistically significant (P 0.05), the improvement of visual acuity in the treatment group was better than that in the control group (P 0.05).Both the treatment group and the control group improved the fundus, the treatment group improved the fundus better than the control group, there was statistical significance after treatment, the treatment group improved the score of TCM syndromes, the control group did not improve the score of TCM syndromes.After treatment, the total effective rate of TCM syndrome in the treatment group was 81.3 and that in the control group was 13.3.The curative effect of TCM syndrome in the treatment group was obviously better than that in the control group.The difference between the two groups was statistically significant (P 0.01).Conclusion: Daming Yin has obvious intervention effect on MPV PDWN P-LCR in patients with deficiency of qi and yin and blood stasis obstruction of collaterals. Meanwhile, it can improve the syndromes and visual function of NPDR.The mechanism may be to regulate the internal environment, reduce the obstruction and injury of capillary wall, reduce the permeability of capillary, protect the intravascular barrier, improve the retinal microcirculation and control the occurrence and development of NPDR.
【學位授予單位】：黑龍江中醫(yī)藥大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R276.7

【參考文獻】

相關期刊論文 前10條

1 羅曉欽;周振峰;;滋陰明目湯治療單純型糖尿病視網膜病變23例臨床觀察[J];湖南中醫(yī)雜志;2017年02期

2 鐘仲輝;;復方血栓通膠囊治療糖尿病性視網膜病變患者的臨床療效[J];中國藥物經濟學;2016年12期

3 石亮;張智慧;李曉宇;呂莉莉;孫蓉;;柴胡水提物對大鼠解熱作用機制研究[J];中國藥物警戒;2016年09期

4 朱成義;伊瓊;馬金力;韋企平;;銀杏葉提取物對糖尿病視網膜病變的臨床療效評價[J];國際眼科雜志;2016年02期

5 馬云成;駱曉琴;丁汝新;;玻璃體腔注射雷珠單抗治療嚴重增生型糖尿病視網膜病變的臨床觀察[J];國際眼科雜志;2016年01期

6 杜晶;李詩國;呂艷葉;;和血明目片治療糖尿病視網膜病變臨床觀察[J];浙江中西醫(yī)結合雜志;2015年12期

7 江蕊;鄭永征;任秉儀;劉光輝;;銀杏葉提取液對糖尿病視網膜病變神經保護的影響[J];國際眼科雜志;2015年08期

8 周榮奎;徐洋;韓f f ;;羥苯磺酸鈣治療非增殖期糖尿病視網膜病變的臨床觀察[J];北方藥學;2015年06期

9 何柳;劉振杰;藍柳貴;羅露露;;丹參注射液眼部離子導入治療糖尿病性視網膜病變臨床觀察[J];中醫(yī)學報;2015年05期

10 李海燕;畢春潮;屈超義;;平均血小板容積與糖尿病視網膜病變嚴重程度的橫斷面研究[J];眼科新進展;2014年08期

，

本文編號：1761748